Recent Investment Analysts’ Ratings Changes for Summit Therapeutics (SMMT)

A number of firms have modified their ratings and price targets on shares of Summit Therapeutics (NASDAQ: SMMT) recently:

• 6/1/2026 – Summit Therapeutics had its “overweight” rating reaffirmed by KeyCorp.
• 5/22/2026 – Summit Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 5/22/2026 – Summit Therapeutics was downgraded by HC Wainwright from “buy” to “neutral”.
• 5/21/2026 – Summit Therapeutics is now covered by Sanford C. Bernstein. They set an “underperform” rating and a $7.70 price target on the stock.
• 5/21/2026 – Summit Therapeutics was upgraded by Sanford C. Bernstein to “strong sell”.
• 5/18/2026 – Summit Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/10/2026 – Summit Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/4/2026 – Summit Therapeutics had its price target lowered by HC Wainwright from $30.00 to $23.00. They now have a “buy” rating on the stock.
• 5/2/2026 – Summit Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/1/2026 – Summit Therapeutics had its price target lowered by Piper Sandler from $17.00 to $16.00. They now have a “neutral” rating on the stock.
• 4/21/2026 – Summit Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity at Summit Therapeutics

In other Summit Therapeutics news, CEO Mahkam Zanganeh purchased 100,000 shares of the stock in a transaction on Thursday, June 4th. The shares were purchased at an average price of $14.60 per share, with a total value of $1,460,000.00. Following the acquisition, the chief executive officer directly owned 25,824,474 shares of the company’s stock, valued at $377,037,320.40. This represents a 0.39% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Manmeet Singh Soni purchased 50,000 shares of the stock in a transaction on Thursday, June 4th. The stock was acquired at an average cost of $14.45 per share, for a total transaction of $722,500.00. Following the acquisition, the chief financial officer directly owned 3,123,603 shares in the company, valued at approximately $45,136,063.35. This trade represents a 1.63% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 250,000 shares of company stock worth $3,642,500 in the last ninety days. 83.50% of the stock is currently owned by insiders.

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.